Literature DB >> 12778772

[Fabry disease: new clinical research--current therapeutic perspectives].

Michael Beck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12778772     DOI： 10.1007/bf03040318

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  10 in total

1.  Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.

Authors:  D F Moore; L T Scott; M T Gladwin; G Altarescu; C Kaneski; K Suzuki; M Pease-Fye; R Ferri; R O Brady; P Herscovitch; R Schiffmann
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Anderson-Fabry disease in Austria.

Authors:  Matthias Lorenz; Anna-Christina Hauser; Margot Püspök-Schwarz; Peter Kotanko; Ingrid Arias; Herbert Zodl; Reinhard Kramar; Eduard Paschke; Till Voigtländer; Gere Sunder-Plassmann
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

3.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

4.  Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.

Authors:  Gert De Schoenmakere; Dominique Chauveau; Jean-Pierre Grünfeld
Journal:  Nephrol Dial Transplant       Date:  2003-01       Impact factor: 5.992

5.  Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

Authors:  David F Moore; Gheona Altarescu; Geoffrey S F Ling; Neal Jeffries; Karen P Frei; Thais Weibel; Gustavo Charria-Ortiz; Raymond Ferri; Andrew E Arai; Roscoe O Brady; Raphael Schiffmann
Journal:  Stroke       Date:  2002-02       Impact factor: 7.914

6.  Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

Authors:  B Sachdev; T Takenaka; H Teraguchi; C Tei; P Lee; W J McKenna; P M Elliott
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

7.  Patients with Fabry disease on dialysis in the United States.

Authors:  Ravi Thadhani; Myles Wolf; Michael L West; Marcello Tonelli; Robin Ruthazer; Gregory M Pastores; Gregorio T Obrador
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

8.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

9.  Anderson-Fabry disease with cerebrovascular complications in two Italian families.

Authors:  W Borsini; G Giuliacci; F Torricelli; E Pelo; F Martinelli; M R Scordo
Journal:  Neurol Sci       Date:  2002-06       Impact factor: 3.307

10.  Clinical features of Fabry's disease in Australian patients.

Authors:  J Galanos; K Nicholls; L Grigg; L Kiers; A Crawford; G Becker
Journal:  Intern Med J       Date:  2002-12       Impact factor: 2.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.